If approved, we believe that etripamil nasal spray will be a valuable treatment option for patients suffering from PSVT. The NDA for etripamil
In a new study, etripamil, a rapid- and short-acting investigational medication formulated to be delivered via nasal spray, restored a normal
Etripamil nasal spray, an investigational treatment, would be the PSVT patients; the timing of the NDA submission for etripamil nasal spray
etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Per the FDA, the NDA for etripamil to treat PSVT
PubMed journal article: Efficacy of etripamil nasal spray for acute conversion of supraventricular tachycardia: a network meta-analysis.
Etripamil nasal spray is being developed for self-administration by patients for the treatment of paroxysmal supraventricular tachycardia.
Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PVST). Etripamil is an
Etripamil nasal spray has been found to be a safe self-treatment for paroxysmal supraventricular tachycardia without medical supervision.
CARDAMYST (etripamil) nasal spray, the conditionally approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3
Comments